India marks its fifth $1B drugmaker

Zydus Cadila has joined the $1 billion-turnover club of Indian drugmakers. It was a $400 million company just four years ago, and planned for the ascent to $1 billion. It hopes to reach $3 billion by 2015. Cadila is welcomed to the club by Cipla, Ranbaxy, GSK and Piramal Group. Story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)